Our Research Approach
We are building Hemab to reimagine care for people living with coagulation disorders who experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. By leveraging our deep understanding of the underlying biology of blood coagulation, we are developing targeted therapies for bleeding and thrombotic disorders like Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and others.
Every Hemab program begins by listening to people who live with their conditions and learning about what they still need.
Lived experiences reveal bleeding patterns, treatment challenges, and daily impacts invisible to conventional research.
Our therapeutic candidates are designed to connect with the body’s natural clotting proteins in a very precise way. This helps protect them from breaking down and lets them build up to levels that can help stop bleeding. In some cases, the treatment keeps the protein active; in others, it turns it off, giving us the flexibility to treat different clotting problems. When needed, our technology can also help guide these proteins to the site of an injury to support healing.
Time to leapfrog therapeutics is now.
We are building a franchise designed to address select coagulation disorders where we believe advances in biology, drug modality, and care delivery have the potential to meaningfully improve disease management.
Decades of Treatment Neglect.
For decades, certain bleeding disorders have remained in the shadows as research and innovation focused elsewhere.
At Hemab, we exist specifically for people with conditions like Glanzmann Thrombasthenia, FVII Deficiency, and von Willebrand Disease—conditions where treatment options have changed little despite scientific advances elsewhere.
Overlooked voices, unmet needs
Every Hemab program starts with the experts who understand these conditions most intimately—the people living with them every day.
These conversations reveal what clinical literature often misses: the anxiety of unpredictable bleeding, the careful planning required for everyday activities, and the nuanced impact these conditions have on daily life that may not be fully captured in standard clinical assessments.
Harnessing new possibilities in therapeutics.
Our therapeutic approach works in harmony with the body's natural clotting processes. We remain technology-agnostic, selecting the optimal scientific approach for each specific condition.
We believe this allows us to develop treatments that can:
• Shield essential clotting proteins from premature breakdown
• Enable these proteins to accumulate to levels that prevent bleeding
• Precisely control activation or deactivation within the clotting cascade
• Direct these proteins to injury sites where they're needed most
We believe this precision will allow us to address different bleeding conditions with targeted solutions rather than generic approaches.
Pipeline
We are building a franchise designed to address select coagulation disorders where we believe advances in biology, drug modality, and care delivery have the potential to meaningfully improve disease management.
Future Pipeline Development
Our technology platform and patient-focused approach positions us to expand into additional overlooked bleeding and thrombotic disorders. We're committed to developing five development projects by 2025 to transform treatment where innovation has been limited.
Looking Beyond the Horizon: We're actively researching additional conditions where our approach could address significant unmet needs.
If you have questions about our ongoing clinical trials, please get in touch with our Medical team
VELORA Pioneer— HMB-002 for Von Willebrand Disease (NCT06754852)
Velora Pioneer is a Phase 1/2 clinical trial of HMB-002 for Von Willebrand Disease (VWD). HMB-002 is being developed as a prophylactic treatment to support restoration of hemostasis in people with VWD using a convenient subcutaneous treatment administration.
VELORA Discover Screening Study for Von Willebrand Disease (NCT06610201)
Velora Discover is a prospective natural history study of patients with Von Willebrand Disease (VWD) to establish baseline disease characteristics, bleeding patterns, and quality of life measures. The purpose of the study is to provide contemporary control data and contextualize treatment effects observed in the interventional components of the Velora Pioneer clinical trial.
Sutacimig for Congenital Factor VII Deficiency (NCT07347249)
This Phase 2 clinical trial evaluates pharmacokinetics, pharmacodynamics, and preliminary safety and tolerability of single ascending doses of sutacimig in patients with Factor VII deficiency. This trial aims to establish proof-of-concept by demonstrating sutacimig’s ability to increase Factor VII levels in patients with Factor VII deficiency.
Sutacimig for Glanzmann Thrombasthenia (NCT06211634)
The goal of this Phase 1/2 clinical trial is to investigate the safety, tolerability, pharmacokinectics, pharmacodynamics and clinical efficacy of stuacimig in patients with Glanzmann thrombasthenia. We have completed the Part A (single ascending dose) and Part B (three-month multiple ascending dose) portions of the trial, and the Part C (long-term extension up to 24 months) portion is currently ongoing.
